qGenomics is the first spin-off company of the CRG. Born with the objective of translating the last advances in genomics research into diagnostic products for the benefit of society, qGenomics first product is a DNA microarray chip for the detection of chromosomal abnormalities at the origin of a number of pathologies. In particular, the application of that chip in prenatal diagnosis provides higher speed, throughput and resolution than traditional karyotyping methods for detecting genomic variation, such as FISH or g-banding. In the future, the company plans to expand its portfolio of products by developing DNA chips for the identification of chromosomal abnormalities in embryos, or to help the diagnosis of cancer, etc.
Physically located at the Barcelona Biomedical Research Park, qGenomics arises as a joint initiative of the CRG and the Pompeu Fabra University, with the additional support of Genoma España, the “Foundation for the development of genomics and proteomics research” in Spain.